Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Akero Therapeutics Inc
(NQ:
AKRO
)
23.50
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Akero Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
August 31, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
August 28, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 11, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Inc. (NASDAQ: AKRO) is a Stock Spotlight on 6/9
June 09, 2023
Via
Investor Brand Network
Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
June 23, 2023
Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responses
From
Akero Therapeutics
Via
GlobeNewswire
3 Mid Caps You Haven't Heard Of But Need To Know About
June 09, 2023
Here are three mid-cap stocks that will not have been on the radar for most readers but whose recent performance warrants closer inspection and consideration.
Via
MarketBeat
Exposures
Product Safety
Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
June 05, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
June 01, 2023
Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at the Jefferies Healthcare Conference
May 31, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
May 16, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
March 29, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 17, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
January 10, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
December 21, 2022
From
Akero Therapeutics
Via
GlobeNewswire
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
December 08, 2022
Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
November 10, 2022
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
November 07, 2022
Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 04, 2022
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
October 11, 2022
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics (NASDAQ: AKRO) Squeezes Shorts After Stronger-then-Expected Results from Phase 2b HARMONY Study of EFX
September 13, 2022
Akero Therapeutics, Inc. (NASDAQ: AKRO) is engaged as a clinical-stage biotechnology company that is focused on the research and development
Via
Spotlight Growth
Akero Therapeutics Inc. (NASDAQ: AKRO) Sets New 52-Week High in Tuesday Morning Session
September 13, 2022
Via
Investor Brand Network
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.